AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Launched by PEERBRIDGE HEALTH, INC · Nov 18, 2024
Trial Information
Current as of June 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new artificial intelligence (AI) tool that helps doctors assess how well the heart is pumping blood, specifically looking at a measurement called ejection fraction (EF). The trial uses a wearable device called the Peerbridge COR® ECG Monitor, which can be worn like a patch during daily activities. Participants will wear this monitor for five minutes while sitting comfortably, and the AI will analyze the heart's electrical signals to estimate the EF. The results from this AI tool will be compared to traditional heart imaging tests to see how accurately it can measure EF severity.
To be eligible for the study, participants must be at least 18 years old and able to wear the monitor. However, individuals who are on certain types of life-support treatments, or who have specific health issues that might make it unsafe to participate, will not be included. Those who decide to join the trial can expect to wear the monitor and provide information about their heart health, contributing to important research that could improve heart assessments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Able and eligible to wear a Holter monitor
- Exclusion Criteria:
- • Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1
- • Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant
- • History of poor tolerance or severe skin reactions to ECG adhesive materials
About Peerbridge Health, Inc
Peerbridge Health, Inc. is a forward-thinking clinical trial sponsor dedicated to advancing healthcare through innovative research and technology. With a focus on enhancing patient outcomes, the company specializes in the development and management of clinical trials that leverage cutting-edge methodologies and data analytics. Peerbridge Health collaborates with healthcare providers, researchers, and regulatory bodies to streamline trial processes and ensure compliance, ultimately aiming to bring effective therapies to market faster. Committed to transparency and patient-centric approaches, Peerbridge Health is at the forefront of transforming clinical research into actionable healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Hackensack, New Jersey, United States
Greensboro, North Carolina, United States
Austin, Texas, United States
Orange, California, United States
New York, New York, United States
Melbourne, Florida, United States
Weslaco, Texas, United States
Patients applied
Trial Officials
Andrea Natale, MD
Principal Investigator
Texas Cardiac Arrhythmia Research Foundation
Johanna P Contreras, MD
Principal Investigator
MOUNT SINAI HOSPITAL
Sachin Parikh, MD
Principal Investigator
Henry Ford Hospital
Brian Kolski, MD
Principal Investigator
Orange County Heart Institute
Daniel Bensimhon, MD
Principal Investigator
Moses H. Cone Memorial Hospital
Sandeep Gulati, PhD
Principal Investigator
Peerbridge Health, Inc
Frank Mazzola, MD
Principal Investigator
South Heart Clinic
Sameer Jamal, MD
Principal Investigator
Hackensack Meridian Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported